Fig. 4: PFS and OS in exploratory subgroups.
From: Genomically matched therapy in advanced solid tumors: the randomized phase 2 ROME trial
a, PFS in hTMB (P = 0.0211). b, OS in hTMB (P = 0.8549). c, MSI-H PFS (P = 0.0062). d, MSI-H OS (P = 0.1737). e, BRAF alterations PFS (P = 0.0033). f, BRAF alterations OS (P = 0.1046). g, HER2 alterations PFS (P = 0.0022). h, HER2 alterations OS (P = 0.1261). Statistical test used to calculate P values: log-rank test. P values derived from exploratory analyses should be interpreted with caution, as these analyses are hypothesis generating rather than confirmatory. Due to the non-predefined nature of exploratory endpoints and the potential for an inflated α level, the statistical significance observed in these analyses serves primarily to generate hypotheses for future confirmatory studies rather than providing definitive evidence NE, not evaluable; NR, not reached.
